Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 4

2(40.0%)

5Total

Phase 1(3)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07477912Phase 1Recruiting

Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT07162571Phase 1Not Yet Recruiting

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

Role: lead

NCT03619252Phase 4Completed

Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

Role: lead

NCT04281797Unknown

Intestinal Microbiome Dynamics in Solid Organ and Stem Cell Transplant Recipients

Role: lead

NCT04483934Phase 1Completed

Treatment of Patients With Non-healing Wounds and Trophic Ulcers Using Autologous Dermal Fibroblasts

Role: collaborator

NCT02966457Phase 4Completed

A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)

Role: lead

All 6 trials loaded